J&J Beats in Q4 With in Line Guidance; so Why Is Its Stock Falling?

Seeking AlphaJan 23 00:04

Intra-Cellular Ticks Higher as J&J Forecasts Early Q2 Close

Seeking AlphaJan 22 23:30

Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook

BenzingaJan 22 21:21

RBC Capital Downgrades Intra-Cellular Therapies(ITCI.US) to Hold Rating, Raises Target Price to $132

Futu NewsJan 22 20:34 · Ratings

RBC Downgrades Intra-Cellular Therapies to Sector Perform From Outperform on Proposed Sale to Johnson & Johnson

MT NewswiresJan 22 19:35

Express News | Intra-Cellular Therapies Inc : RBC Cuts to Sector Perform From Outperform; Raises Target Price to $132 From $108

BreakingsJan 22 13:14